Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Stem Cells & Cell Therapy Summit

Jef Pinxteren's Biography

Jef Pinxteren, Manager & Head, Regenesys

He obtained his PhD in Biochemistry at the University of Antwerp in 1994. With a long-term EMBO fellowship he moved to the UK to study the role of G-proteins in secretion from granulocytes. This was in the group of Bastien Gomperts and Peter Tatham at University College London. After his fellowship he obtained further funding from the Medical Research Council (MRC) and the Wellcome Trust. In both 1999 and 2000, he received a UCL Bogue fellowship to work in the US with Vytas Bankaitis, first at UAB in Alabama, later at Chapel Hill in North Carolina. In this project a mouse ES cell model was used to establish a role for phosphoinositol transfer protein (PITP) in secretion from granulocytes.
In 2000 he returned to Belgium and he joined the group of Jean Plum and Bart Vandekerckhove at the University of Gent for a project on cord blood derived stem cells. He started work on human MAPC and collaborated with Catherine Verfaillie in Minneapolis. In 2004 he started to perform proteomics on human MAPC and moved to the VIB (Flemish Institute of Biotechnology) where he joined the group of Joel Vandekerckhove and Kris Gevaert.
In 2006, he moved to the newly formed Stem Cell Institute Leuven under Catherine Verfaillie and worked with Athersys (Cleveland, Ohio) to set up the daughter company ReGenesys. In May 2007 he started to work as Head R&D of ReGenesys. With support from the EU Framework Program and IWT, the R&D support agency of the Flemish government, he built out ReGenesys with a 12–head strong research team. The focus of the team is developing a xeno-free version of the MultiStem® product and alternative and more compact ways of expanding the product for clinical production.

Jef Pinxteren Image

Developing a Next Generation MultiStem Product; a Xeno-free Formulation and Alternative Methods for Production and Scale-up

Friday, 6 September 2013 at 09:45

Add to Calendar ▼2013-09-06 09:45:002013-09-06 10:45:00Europe/LondonDeveloping a Next Generation MultiStem Product; a Xeno-free Formulation and Alternative Methods for Production and Scale-upStem Cells and Cell Therapy Summit in London, UKLondon,

ReGenesys is a biopharmaceutical company focused on the research, development and commercialization of stem cell-based therapies and technologies. MultiStem® cells are bone marrow-derived non-hematopoietic adherent stem cells with a large expansion capacity and a remarkable biological plasticity. MultiStem cells have the potential to home and integrate into damaged tissues and provide immunomodulatory, angiogenic and other effects by cell-cell contact and paracrine regulation. Therefore, there is growing interest in the use of MultiStem therapy. The MultiStem product is an allogeneic “off the shelf" stem cell product. Like mesenchymal stem cells (MSC), allogeneic MultiStem cells are non-immunogenic and exert immunosuppressive effects in vitro. On the other hand, MultiStem cells show alterations in phenotype, differences in gene and protein expression and have an extensive proliferation capacity as compared to MSC. MultiStem cells are currently being used in mid-stage clinical trials for ischemic stroke (Phase II) and ulcerative colitis (Phase II). Two phase I trials were earlier concluded successfully (GVHD and AMI) and other trials are being prepared, e.g. in solid organ transplantation.

Add to Calendar ▼2013-09-05 00:00:002013-09-06 00:00:00Europe/LondonStem Cells and Cell Therapy SummitStem Cells and Cell Therapy Summit in London, UKLondon,